Pain Clinical Trial
Official title:
A Pilot Clinical Trial of Lenalidomide (Revlimid®) for the Treatment of Refractory Cancer Pain
The goal of this clinical research study is to learn if lenalidomide can help to treat
uncontrolled pain caused by advanced cancer.
Primary Objectives:
1. Determine efficacy of Lenalidomide for the treatment of refractory cancer pain, as
measured by the change on Edmonton symptom assessment scale (ESAS).
Secondary Objectives:
1. To determine the effect of Lenalidomide on fatigue, sleep, depressed mood, nausea and
appetite/anorexia.
2. Determine changes in serum levels of inflammatory cytokines (IL-1beta, IL-6, TNF-alpha,
interferon(IFN)-alpha and IFN-gamma, and C-reactive protein) before and after treatment
with Lenalidomide.
3. Effect of Lenalidomide on T-cell subsets especially T-regulatory cells
4. Effect of Lenalidomide on the expression of costimulatory receptors, CD80, CD86, and
CD40, on myeloid and plasmacytoid dendritic cells
5. Safety (type, frequency, severity, and relationship of adverse events to study
treatment)
The Study Drug:
Lenalidomide is designed to change the body's immune system. It may also interfere with the
development of tiny blood vessels that help support tumor growth. Therefore, in theory, it
may decrease or prevent the growth of cancer cells. The drug is also designed to decrease
the level of certain proteins in the blood called cytokines, which may result in decreased
pain.
Study Drug Administration:
If you are found to be eligible to take part in this study, you will take lenalidomide
capsules each morning, with or without food. Take lenalidomide capsules whole, with a
4-ounce (1/2 cup) glass of water at the same time each day. Do not break, chew, or open the
capsules. If you miss a dose of lenalidomide, take it as soon as you remember on the same
day. If you miss taking your dose for the entire day, take your regular dose the next
scheduled day (do NOT take double your regular dose to make up for the missed dose).
If you take too much lenalidomide, call your study doctor or health care provider or poison
control center right away.
You will also be allowed to take strong pain killers such as morphine as prescribed by your
study doctor for pain. If you need more than 3 doses of these pain killers in a 24-hour
period, you should call your study doctor.
Study Visits:
You will visit the clinic throughout the study. At each visit, you will be asked to return
any unused study drug and empty bottles to the clinic and you will be asked about any side
effects you may be experiencing. The last study visit will be on Day 43 or Day 57, depending
on the side effects you may experience. The following tests and procedures will be
performed:
On Day 8:
Blood (about 1 tablespoon) will be drawn for routine tests and women who are able to have
children will have a blood pregnancy test.
Day 15:
Blood (about 1 tablespoon) will be drawn for routine tests. Women who are able to have
children will have a blood (1-2 teaspoons) pregnancy test. You will complete 5
questionnaires about the pain, the pain symptoms, and any side effects you may be having.
The questionnaires will take about 30 to 40 minutes to complete. Women who are able to have
children will have a blood pregnancy test.
Day 22:
Blood (about 1 tablespoon) will be drawn for routine tests. Women who are able to have
children will have a blood (1-2 teaspoons) pregnancy test.
Day 29:
You will complete the same questionnaires as on Day 15. Women who are able to have children
will have a blood pregnancy test and will be counseled about pregnancy precautions and
risks. Blood (about 1 tablespoon) will be drawn for routine tests. Women who are able to
have children will have a blood (1-2 teaspoons) pregnancy test.
Day 36:
Blood (about 1 tablespoon) will be drawn for routine tests.
Day 43:
Blood (about 1 tablespoon) will be drawn for routine tests. You will complete the same
questionnaires as on Day 15. If this is your last visit, you will have an ECG. Women who are
able to have children will have a blood (1-2 teaspoons) pregnancy test.
Day 57 (if necessary):
You will complete the same questionnaires as on Day 15. Blood (about 1 tablespoon) will be
drawn for routine tests. You will complete the same questionnaires as on Day 15. If this is
your last visit, you will have an ECG. Women who are able to have children will have a blood
(1-2 teaspoons) pregnancy test.
Day 71 (if necessary):
If you stopped taking the drug on Day 57, a blood (1-2 teaspoons) pregnancy test will be
done.
Length of Study:
You may take lenalidomide for up to 57 days. You will be taken off study if the disease gets
worse or if intolerable side effects occur.
If you are a female who is able to have children and you do take lenalidomide for all 57
days, you will be required to have a blood (1-2 teaspoons) pregnancy test 28 days after your
last dose of lenalidomide.
The routine blood draws on Days 8, 22, and 36 may done at your home (by a study nurse),
local doctor's office, or at M. D. Anderson.
All patients who were on lenalidomide and then stopped taking it, will be checked every 3 to
5 weeks for a period of 1 year. During the follow-up visits, certain tests and procedures
will be performed. These include a symptom questionnaire, blood draw for routine tests, a
check of your side effects, and pregnancy testing for women who are still able to become
pregnant. These are the same tests that were done while you were on the study.
Daily Drug Diary and Questionnaire:
Starting on Day 1 until the end of the study, you will complete a questionnaire once daily
about any symptoms and pain you may be experiencing. It will take about 5 minutes to
complete each time. You will also be provided with a drug diary to write down when and how
often you take pain medication. You should bring your completed diary to each study visit so
it can be reviewed by the research nurse.
Phone Call Follow-up:
You will be contacted by telephone at home to be asked questions about your symptoms and any
side effects you may have experienced. You will be called on Day 8 (plus or minus 3 days),
Day 22 (plus or minus 3 days) and Day 36 (plus or minus 3 days). The phone calls will last
about 10-15 minutes each time.
End-of-Study Visit:
You will come to the clinic 28 days after your last dose of lenalidomide for a follow-up
visit. You will be checked for side effects, and women who are able to have children must
have a negative blood (1-2 teaspoons) pregnancy test.
This is an investigational study. Lenalidomide is approved by FDA for the treatment of
myelodysplastic syndrome (MDS) and in combination with dexamethasone for patients with
multiple myeloma (MM). Lenalidomide is not FDA approved for pain relief. Its use in this
study is investigational. If you experience intolerable pain after you stop receiving the
study drug, you will be allowed to start receiving lenalidomide (off study). You will be
monitored for side effects for every 2-3 weeks while you are on this medication for a period
of 1 year. Up to 15 patients will take part in this study. All will be enrolled at M. D.
Anderson.
;
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05559255 -
Changes in Pain, Spasticity, and Quality of Life After Use of Counterstrain Treatment in Individuals With SCI
|
N/A | |
Completed |
NCT04748367 -
Leveraging on Immersive Virtual Reality to Reduce Pain and Anxiety in Children During Immunization in Primary Care
|
N/A | |
Terminated |
NCT04356352 -
Lidocaine, Esmolol, or Placebo to Relieve IV Propofol Pain
|
Phase 2/Phase 3 | |
Completed |
NCT05057988 -
Virtual Empowered Relief for Chronic Pain
|
N/A | |
Completed |
NCT04466111 -
Observational, Post Market Study in Treating Chronic Upper Extremity Limb Pain
|
||
Recruiting |
NCT06206252 -
Can Medical Cannabis Affect Opioid Use?
|
||
Completed |
NCT05868122 -
A Study to Evaluate a Fixed Combination of Acetaminophen/Naproxen Sodium in Acute Postoperative Pain Following Bunionectomy
|
Phase 3 | |
Active, not recruiting |
NCT05006976 -
A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study
|
N/A | |
Completed |
NCT03273114 -
Cognitive Functional Therapy (CFT) Compared With Core Training Exercise and Manual Therapy (CORE-MT) in Patients With Chronic Low Back Pain
|
N/A | |
Enrolling by invitation |
NCT06087432 -
Is PNF Application Effective on Temporomandibular Dysfunction
|
N/A | |
Completed |
NCT05508594 -
Efficacy and Pharmacokinetic-Pharmacodynamic Relationship of Intranasally Administered Sufentanil, Ketamine, and CT001
|
Phase 2/Phase 3 | |
Recruiting |
NCT03646955 -
Partial Breast Versus no Irradiation for Women With Early Breast Cancer
|
N/A | |
Active, not recruiting |
NCT03472300 -
Prevalence of Self-disclosed Knee Trouble and Use of Treatments Among Elderly Individuals
|
||
Completed |
NCT03678168 -
A Comparison Between Conventional Throat Packs and Pharyngeal Placement of Tampons in Rhinology Surgeries
|
N/A | |
Completed |
NCT03286543 -
Electrical Stimulation for the Treatment of Pain Following Total Knee Arthroplasty Using the SPRINT Beta System
|
N/A | |
Completed |
NCT03931772 -
Online Automated Self-Hypnosis Program
|
N/A | |
Completed |
NCT02913027 -
Can We Improve the Comfort of Pelvic Exams?
|
N/A | |
Terminated |
NCT02181387 -
Acetaminophen Use in Labor - Does Use of Acetaminophen Reduce Neuraxial Analgesic Drug Requirement During Labor?
|
Phase 4 | |
Recruiting |
NCT06032559 -
Implementation and Effectiveness of Mindfulness Oriented Recovery Enhancement as an Adjunct to Methadone Treatment
|
Phase 3 | |
Active, not recruiting |
NCT03613155 -
Assessment of Anxiety in Patients Treated by SMUR Toulouse and Receiving MEOPA as Part of Their Care
|